NCL was highly expressed during fetal forebrain neocortex development, at gestational week 18 (GW18) and GW22, significantly downregulated in the adult brain, and upregulated in brain tumors, as revealed by immunofluorescence staining against NCL and the nuclear marker TO-PRO-3 (55) (Figure 1, A–C and P). The gene discussed is NUCLEOLIN; the disease is brain neoplasm.